Worldwide Clinical Trials Acquires Catalyst in Strategic Oncology Push

RESEARCH TRIANGLE PARK, NC – February 16, 2026 – In a significant move underscoring the trend of consolidation and specialization within the clinical research industry, global contract research organization (CRO) Worldwide Clinical Trials has completed its acquisition of Catalyst Clinical Research. The deal brings Catalyst, a highly regarded specialist in oncology trials and functional service provider (FSP) models, into the fold of the larger, global CRO, creating a combined entity of approximately 4,400 employees across more than 70 countries.

The acquisition, the financial terms of which were not disclosed, strategically positions Worldwide to deepen its expertise in the highly complex and rapidly growing field of oncology research. It also significantly bolsters its FSP capabilities, a flexible outsourcing model gaining increasing traction among biopharmaceutical clients seeking scalable and cost-effective development solutions.

“The acquisition of Catalyst strengthens Worldwide’s capabilities in a very deliberate way, building a stronger, more capable CRO partner for our customers,” said Alistair Macdonald, Chief Executive Officer of Worldwide. He noted the deal “expands our reach into earlier phase oncology, adds targeted FSP and biometrics capabilities, and accelerates our technology platforms.”

A Strategic Play in a Consolidating Market

The move comes at a time of intense activity and growth in the global CRO market. Valued at nearly $70 billion in 2023, the sector is projected to expand at a compound annual growth rate of nearly 10%, potentially reaching over $130 billion by 2030. This growth is fueled by robust R&D spending from pharmaceutical and biotech companies and an increasing reliance on outsourcing complex clinical trial functions.

Within this expanding market, a powerful trend of consolidation has emerged. Large and mid-sized CROs are actively pursuing mergers and acquisitions to achieve greater scale, broaden their therapeutic expertise, and expand their geographic footprint. By acquiring niche players with specialized skills, larger organizations can offer a more comprehensive, end-to-end service portfolio, making them more competitive against industry giants like IQVIA and Labcorp Drug Development.

Worldwide's acquisition of Catalyst fits perfectly within this strategic paradigm. It transforms Worldwide into a more formidable competitor by integrating a sought-after specialty, allowing the company to offer a more robust suite of services that span the full drug development lifecycle, from early-phase discovery to late-phase global trials.

Doubling Down on Oncology and Flexible Services

The core of the deal's strategic value lies in combining Catalyst's specialized focus with Worldwide's global scale. Oncology is the single largest and one of the most complex therapeutic areas in clinical research. The oncology CRO market alone was valued at over $12 billion in 2023 and is on a trajectory to more than double by the early 2030s, driven by a pipeline rich with innovative but complex therapies like cell and gene therapies.

Catalyst carved out a strong reputation for its deep expertise in navigating the intricacies of early-phase oncology trials. By integrating this capability, Worldwide can now offer its biopharma partners a seamless path for their cancer drug candidates, from first-in-human studies through to large-scale registration trials. This is particularly attractive to the small and mid-sized biotech companies that are often at the forefront of oncology innovation but lack the internal resources to manage these complex programs.

Equally important is the enhancement of Worldwide’s Functional Service Provider (FSP) offerings. The FSP market, where clients outsource specific functions like data management or clinical monitoring rather than an entire trial, is itself a high-growth sector projected to exceed $55 billion by 2032. Catalyst’s established FSP model, Catalyst Flex, provides Worldwide with a proven, scalable platform to meet rising client demand for more adaptable and tailored outsourcing partnerships.

The Private Equity Blueprint for Growth

Behind this strategic industry move is the influential hand of private equity, a key driver of M&A activity in the CRO sector. Worldwide Clinical Trials is a portfolio company of Kohlberg & Company, which acquired a majority stake in 2023. Catalyst, meanwhile, was backed by QHP Capital, a healthcare-focused investment firm. This transaction represents a classic private equity playbook: a larger, PE-backed platform company (Worldwide) acquiring a smaller, specialized company to accelerate growth and enhance market position, resulting in a successful exit for the seller's investors (QHP Capital).

“The completion of the Catalyst acquisition deepens Worldwide’s oncology offering and global reach,” commented Matt Jennings, Executive Chairman of Worldwide and Senior Operating Partner at Kohlberg. He described Catalyst’s expertise and technology as a “natural fit for Worldwide” that reinforces the strategy to “build a differentiated, technology-enabled CRO.”

This investment strategy hinges on identifying and combining complementary strengths to create an entity that is more valuable than the sum of its parts. By funding strategic acquisitions, private equity firms like Kohlberg enable their portfolio companies to rapidly scale and adapt to market demands in a way that might be difficult through organic growth alone.

Integrating Teams and Technologies for the Future

As with any major acquisition, the success of the Worldwide-Catalyst union will depend on a smooth and effective integration. Leadership has signaled a focus on continuity and cultural alignment. In a significant move, former Catalyst President and CEO Nik Morton has joined Worldwide as Executive Vice President and Chief Strategy & Transformation Officer. Additionally, Catalyst’s former Chairman, Nick Dyer, has been appointed to Worldwide’s Board of Directors. These appointments suggest a desire to retain critical expertise and institutional knowledge from Catalyst.

“Joining the Worldwide team is an exciting next chapter for Catalyst,” said Morton. “We are energized by the cultural alignment between our teams and share a deep commitment to scientific excellence, operational integrity, and a people-first approach.”

An integration team is now tasked with the complex work of harmonizing technology platforms, operational workflows, and corporate cultures across the newly combined 4,400-person organization. The stated goal is to leverage the best practices from both companies to enhance data transparency and operational efficiency. For biopharma clients, the promise is a more powerful and flexible research partner, better equipped to navigate the challenges of modern drug development and accelerate the delivery of novel therapies to patients worldwide.